The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of patients with rare cancers treated with combination immune checkpoint inhibitors with and without lung and/or liver metastases (NCI/SWOG S1609).
 
Megan Othus
Consulting or Advisory Role - Merck; Refined Oncology
Other Relationship - Bristol-Myers Squibb; Celgene; Glycomimetics; Grifols
 
Yichen Wang
No Relationships to Disclose
 
Young Kwang Chae
Consulting or Advisory Role - AstraZeneca; Biodesix; BMS; Boehringer Ingelheim; Eisai; Foundation Medicine; GeneCker; Guardant Health; Immuneoncia; Lilly; Lunit; Merck; NeoImmuneTech; Novocure; Oncohost; Picture Health; Regeneron; Roche/Genentech; Takeda; Tempus
Speakers' Bureau - AstraZeneca; BMS; G1 Therapeutics; Genentech/Roche; Jazz Pharmaceuticals; Lilly; Merck
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Imagene AI; Lexent Bio; Oncohost; Picture Health; Predicine; Regeneron; Tempus
 
Madison Davies
No Relationships to Disclose
 
Eliana Dietrich
No Relationships to Disclose
 
Sandip Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Compugen; Iovance Biotherapeutics (Inst); Lilly; Lilly; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - A2Bio (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix; XZOM
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Daiichi Sankyo; Datar Genomics; Iylon; Jackson Laboratory for Genomic Medicine; Lanauria Therapeutics; Nova; Precirix; Recordati; Roche; Ryght AI
Speakers' Bureau - AstraZeneca; AstraZeneca; CureMatch; OneCell; Recordati; Tempus
Research Funding - Biological Dynamics (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Guardant Health (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Sysmex (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation
Other Relationship - See Comments